Telavancin injection
Products billed under this code include Vibativ.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Vibativ.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Vibativ | Cumberland Pharmaceuticals Inc. | 66220-0315-22 | 900 | $7,334.10 |
| Vibativ | Cumberland Pharmaceuticals Inc. | 66220-0315-44 | 300 | $2,444.70 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $8.149 | +$0.665 | 10 MG | Telavancin injection | v1, posted September 17, 2026 |
| 3Q26 | $7.484 | +$0.452 | 10 MG | Telavancin injection | v1, posted September 15, 2026 |
| 2Q26 | $7.032 | −$0.336 | 10 MG | Telavancin injection | v1, posted September 15, 2026 |
| 1Q26 | $7.368 | +$0.255 | 10 MG | Telavancin injection | v1, posted September 15, 2026 |
| 4Q25 | $7.113 | −$0.354 | 10 MG | Telavancin injection | v1, posted September 8, 2026 |
| 3Q25 | $7.467 | +$0.377 | 10 MG | Telavancin injection | v1, posted March 10, 2026 |
| 2Q25 | $7.09 | −$0.306 | 10 MG | Telavancin injection | v1, posted March 10, 2026 |
| 1Q25 | $7.396 | +$0.168 | 10 MG | Telavancin injection | v1, posted December 19, 2025 |
| 4Q24 | $7.228 | +$0.168 | 10 MG | Telavancin injection | v1, posted June 11, 2025 |
| 3Q24 | $7.06 | −$0.071 | 10 MG | Telavancin injection | v1, posted June 11, 2025 |
| 2Q24 | $7.131 | +$0.083 | 10 MG | Telavancin injection | v1, posted March 11, 2025 |
| 1Q24 | $7.048 | −$0.105 | 10 MG | Telavancin injection | v1, posted December 19, 2024 |
| 4Q23 | $7.153 | +$0.327 | 10 MG | Telavancin injection | v1, posted October 10, 2024 |
| 3Q23 | $6.826 | −$0.128 | 10 MG | Telavancin injection | v1, posted June 5, 2024 |
| 2Q23 | $6.954 | −$0.029 | 10 MG | Telavancin injection | v1, posted February 23, 2024 |
| 1Q23 | $6.983 | +$0.292 | 10 MG | Telavancin injection | v1, posted December 6, 2023 |
| 4Q22 | $6.691 | −$0.308 | 10 MG | Telavancin injection | v1, posted June 22, 2023 |
| 3Q22 | $6.999 | +$0.667 | 10 MG | Telavancin injection | v1, posted June 9, 2023 |
| 2Q22 | $6.332 | −$0.064 | 10 MG | Telavancin injection | v1, posted December 14, 2022 |
| 1Q22 | $6.396 | +$0.241 | 10 MG | Telavancin injection | v1, posted June 8, 2022 |
| 4Q21 | $6.155 | −$0.506 | 10 MG | Telavancin injection | v1, posted June 2, 2022 |
| 3Q21 | $6.661 | +$0.81 | 10 MG | Telavancin injection | v1, posted June 2, 2022 |
| 2Q21 | $5.851 | −$0.092 | 10 MG | Telavancin injection | v1, posted March 1, 2022 |
| 1Q21 | $5.943 | – | 10 MG | Telavancin injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.